Decreased dipeptidyl peptidase IV enzyme activity of plasma soluble CD26 and its inverse correlation with HIV-1 RNA in HIV-1 infected individuals

Clinical Immunology

Volumn 91, Issue 3, 1999, Pages 283-295

  Hosono, Osamu ^a   Homma, Toshio ^a   Kobayashi, Hiroshi ^a   Munakata, Yasuhiko ^b   Nojima, Yoshihisa ^a   Iwamoto, Aikichi ^a   Morimoto, Chikao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Dipeptidyl peptidase IV; HIV RNA; Soluble CD26

Indexed keywords

ADENOSINE DEAMINASE; DIPEPTIDYL PEPTIDASE IV; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL;

EID: 0033046381     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.1999.4711     Document Type: Article

References (52)

1. Fox D. A., Hussey R. E., Fitzgerald K. A., Acuto O., Poole C., Pallay L., Daley J. R., Schlossman S. F., Reinherz E. L. Ta1, a novel 105 kD human T cell activation antigen defined by a monoclonal antibody. J. Immunol. 133:1984;1250-1256.
2. Morimoto C., Torimoto Y., Levinson G., Rudd C. E., Schrieber M., Dang N. H., Letvin N. L., Schlossman S. F. 1F7, a novel cell surface molecule, involved in helper function of CD4 cells. J. Immunol. 143:1989;3430-3439.
3. Torimoto Y., Dang N. H., Tanaka T., Prado C., Schlossman S. F., Morimoto C. Biochemical characterization of CD26 (dipeptidyl peptidase IV): Functional comparison of distinct epitopes recognized by various anti-CD26 monoclonal antibodies. Mol. Immunol. 29:1992;183-192.
4. Hegen M., Niedobitek G., Klein C. E., Stein H., Fleisher B. The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity. J. Immunol. 144:1990;2908-2914.
5. Yaron A., Naider F. Proline-dependent structural and biological properties of peptides and proteins. Crit. Rev. Biochem. Mol. Biol. 28:1993;31-81.
6. Dang N. H., Torimoto Y., Deusch K., Schlossman S. F., Morimoto C. Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways. J. Immunol. 144:1990;4092-4100.
7. Tanaka T., Kameoka J., Yaron A., Schlossman S. F., Morimoto C. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc. Natl. Acad. Sci. USA. 90:1993;4586-4590.
8. Tanaka T., Camerini D., Seed B., Torimoto Y., Dang N. H., Kameoka J., Dahlberg H. N., Schlossman S. F., Morimoto C. Cloning and functional expression of the T cell activation antigen, CD26. J. Immunol. 149:1992;481-486.
9. Torimoto T., Dang N. H., Vivier E., Tanaka T., Schlossman S. F., Morimoto C. Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J. Immunol. 147:1991;2514-2517.
10. Kameoka J., Tanaka T., Nojima Y., Schlossman S. F., Morimoto C. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science. 261:1993;466-469.
11. Tanaka T., Duke-Cohan J. S., Kameoka J., Yaron A., Lee I., Schlossman S. F., Morimoto C. Enhancement of antigen-induced T-cell proliferation by soluble CD26/DPPIV. Proc. Natl. Acad. Sci. USA. 91:1994;3082-3086.
12. Lane H. C., Depper J. L., Greene W. D., Whalen G., Waldman T. A., Fauci A. S. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome: Evidence for a selective defect in soluble antigen recognition. N. Engl. J. Med. 313:1985;79-84.
13. Van Noesel C. J., Gruters R. A., Terpstra F. G., Schellekens P. T., van Lier R. A., Miedema F. Functional and phenotypic evidence for a selective loss of memory T cells in asymptomatic human immunodeficiency virus-infected men. J. Clin. Invest. 86:1990;293-299.
14. Blazquez M. V., Madueno J. A., Gonzalez R. G., Jurado R., Bachovchin W. W., Pena J., Munoz E. Selective decrease of CD26 expression in T cells from HIV-1-infected individuals. J. Immunol. 149:1992;3073-3077.
15. Gougeon M.-L., Lecoeur H., Callebaut C., Jacotot E., Dulioust A., Roue R., Montagnier L., Hovanessian A. G. Selective loss of the CD4+/CD26+ T-cell subset during HIV infection. Res. Immunol. 147:1996;5-8.
16. Cullen B. R. Does HIV-1 Tat induce a change in viral initiation rights? Cell. 73:1993;417-420.
17. Viscidi R. P., Mayur K., Lederman H. M., Frankel A. D. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. Science. 246:1989;1606-1608.
18. Gutheil W. G., Subramanyan M., Flentke G. R., Sandford D. G., Munoz E., Huber B. T., Bachovchin W. W. Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): A possible mechanism for Tat's immunosuppressive activity. Proc. Natl. Acad. Sci. USA. 91:1994;6594-6598.
19. Callebaut C., Krust B., Jacotot E., Hovanessian A. G. T cell activation antigen, CD26, as a cofactor for entry of HIV in CD4+ cells. Science. 262:1993;2045-2050.
20. Morimoto C., Lord C. I., Zhang C., Duke-Cohan J. S., Letvin N. L., Schlossman S. F. Role of CD26/dipeptidyl peptidase IV in human immunodeficiency virus type 1 infection and apoptosis. Proc. Natl. Acad. Sci. USA. 91:1994;9960-9964.
21. Broder C. C., Nussbaum D., Gutheil W. G., Bachouchin W. W., Berger E. A. CD26 antigen and HIV fusion? Science. 264:1994;1151-1159.
22. Camerini D., Planelles V., Chen I. S. Y. CD26 antigen and HIV fusion? Science. 264:1994;1159-1161.
23. Feng Y., Broder C. C., Kennedy P. E., Berger E. A. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 272:1996;872-877.
24. Dragic T., Litwin V., Allaway G. P., Martin S. R., Huang Y., Nagashima K. A., Cayanan C., Maddon P. J., Koup R. A., Moore J. P., Paxton W. A. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 381:1996;667-673.
25. Alkhatib G., Combadiere C., Broder C. C., Feng Y., Kennedy P. E., Murphy P. M., Berger E. A. CC CKR 5: RANTES, MIP-1α, MIP-1β, receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 272:1996;1955-1958.
26. Callebaut C., Jacotot E., Blanco J., Krust B., Hovanessian A. G. Increased rate of HIV-1 entry and its cytopathic effect in CD4+/CXCR4+ T cells expressing relatively high levels of CD26. Exp. Cell Res. 241:1998;352-362.
27. Morbid. Mortal. Weekly Rep. 41:1993;1-19.
28. Dong R., Kameoka J., Hegen M., Tanaka T., Xu Y., Schlossman S. F., Morimoto C. Characterization of adenosine deaminase (ADA) binding to human CD26 on T cells and its biological role in immune response. J. Immunol. 156:1996;1349-1355.
29. Mellors J. W., Rinaldo C. R. Jr., Gupta P., White R. M., Todd J. A., Kingsley L. A. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 272:1996;1167-1170.
30. Dang N. H., Torimoto Y., Schlossman S. F., Morimoto C. Human CD4 helper T cell activation: Functional involvement of two distinct collagen receptors, 1F7 and VLA integrin family. J. Exp. Med. 172:1990;649-652.
31. Blanco J., Marie I., Callebaut C., Jacotot E., Krust B., Hovanessian A. G. Specific binding of adenosine deaminase but not HIV-1 transactivator protein Tat to human CD26. Exp. Cell Res. 225:1996;102-111.
32. Westendorp M. O., Frank R., Ochsenbauer C., Stricker K., Dhein J., Walczak H., Debatin K. M., Krammer P. H. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature. 375:1995;497-500.
33. Stein H., Schwarting R., Niedobitek G. Cluster report: CD26. Leukocyte Typing IV. 1989;Oxford Univ. Press, Oxford. p. 412.
34. Maes M., Scharpe S., De Meester I., Goossens P., Wauters A., Neels H., Verkerk R., De Meyer F., D'Hondt P., Peeters D., Schotte C., Cosyns P. Components of biologic variation in prolyl endopeptidase and dipeptidyl peptidase IV activity in plasma of healthy subjects. Clin. Chem. 40:1994;1686-1691.
35. Scharpe S., De Meester I., Vanhoof G., Hendriks D., van Sande M., van Camp K., Yaron A. Assay of dipeptidyl peptidase IV in serum by fluorometry of 4-methoxy-2-naphthylamine. Clin. Chem. 34:1988;2299-2301.
36. Chikuma T., Hama T., Nagatsu T., Kumegawa M., Kato T. Purification and properties of dipeptidyl peptidase IV from human urine. Biol. Chem. Hoppe Seyler. 371:1990;325-330.
37. Nilius R., Stuhec K., Dietrich R. Changes of dipeptidyl peptidase IV as a membrane marker of lymphocytes in acute and chronic liver diseases: Biochemical and cytochemical investigations. Physiol. Res. 40:1991;95-102.
38. Stancikova M., Lojda Z., Lukac J., Ruzickova M. Dipeptidyl peptidase IV in patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 10:1992;381-385.
39. Fujita K., Hirano M., Ochiai J., Funabashi M., Nagatsu I., Nagatsu T., Sakakibara S. Serum glycylprolinep. Clin. Chim. Acta. 88:1978;15-20.
40. Fahey J. L., Taylor J. M. G., Detels R., Hofmann B., Melmed R., Nishanian P., Giorgi J. V. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N. Engl. J. Med. 322:1990;166-172.
41. Saag M. S., Holodniy M., Kuritzkes D. R., O'Brien W. A., Coombs R., Poscher M. E., Jacobsen D. M., Shaw G. M., Richman D. D., Volberding P. A. HIV viral load markers in clinical practice. Nature Med. 2:1996;625-629.
42. Jacotot E., Callebaut C., Blanco J., Krust B., Neubert K., Barth A., Hovanessian A. G. Dipeptidyl-peptidase IV-β, a novel form of cell-surface-expressed protein with dipeptidyl-peptidase IV activity. Eur. J. Biochem. 239:1996;248-258.
43. Duke-Cohan J. S., Morimoto C., Rocker J. A., Schlossman S. F. A novel form of dipeptidylpeptidase IV found in human serum: Isolation, characterization, and comparison with T lymphocyte membrane dipeptidylpeptidase IV (CD26). J. Biol. Chem. 270:1995;14107-14114.
44. Hirshhorn R. Adenosine deaminase deficiency. Rosen F. S., Seligmann M. "Immunodeficiency Reviews. 1990;175-198 Howard, London.
45. Murray J. L., Loftin K. C., Munn C. G., Reuben J. M., Mansell P. W., Hersh E. M. Elevated adenosine deaminase and purine nucleoside phosphorylase activity in peripheral blood null lymphocytes from patients with acquired immune deficiency syndrome. Blood. 65:1985;1318-1324.
46. Tsuboi I., Sagawa K., Shichijo S., Yokoyama M. M., Ou D. W., Wiederhold M. D. Adenosine deaminase isoenzyme levels in patients with human T-cell lymphotropic virus type 1 and human immunodeficiency virus type 1 infections. Clin. Diagn. Lab. Immunol. 2:1995;626-630.
47. Schmitz T., Underwood R., Khiroya R., Bachovohim W. W., Huber B. T. Potentiation of the immune response in HIV-1 individuals. J. Clin. Invest. 97:1996;1545-1549.
48. D'Souza M. P., Harden V. A. Chemokines and HIV-1 second receptors. Nature Med. 2:1996;1293-1300.
49. Oravecz T., Pall M., Roderiquez G., Gorrell M. D., Ditto M., Nguyen N. Y., Boykins R., Unsworth E., Norcross M. A. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J. Exp. Med. 186:1997;1865-1872.
50. Proost P., De Meester I., Schols D., Struyf S., Lambeir A-M., Wuyts A., Opdenakker G., De Clercq E., Scharpe S., Van Damme J. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV: Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J. Biol. Chem. 273:1998;7222-7227.
51. Ohtsuki T., Hosono O., Kobayashi H., Munakata Y., Souta A., Shioda T., Morimoto C. Negative regulation of the anti-human immunodeficiency virus and chemotactic activity of human stromal cell-derived factor 1α by CD26/dipeptidyl peptidase IV. FEBS Lett. 431:1998;236-240.
52. Proost P., Struyf S., Schols D., Durinx C., Wuyts A., Lenaerts J. P., De Clercq E., De Meester I., Van Damme J. Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1 α FEBS Lett. 432:1998;73-76.